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ABSTRACT
DISCRIMINATIVE STIMULUS EFFECTS OF PUTATIVE ANTIPSYCHOTIC DRUGS
By
Alex D. Lekander
This study attempted to further explore the discriminative stimulus properties of antipsychotic
drugs, by establishing the typical antipsychotic drug chlorpromazine, and the atypical
antipsychotic drug clozapine as discriminative stimulus in two different groups of rats. The rats
trained to discriminate chlorpromazine from vehicle failed to do so reliably, however nine of ten
rats trained to discriminate 1.25 mg/kg clozapine from vehicle were able to acquire the
discrimination in 19.1 sessions. The clozapine cue partially generalized (63.13% drug lever
responding [SEM = ± 18.91]) to the antimalarial drug methylene blue at the 7.5 mg/kg dose, but
not to the antimalarial quinacrine. This study found that the antimalarial drug methylene blue
may share some pharmacological similarities or subjective effects with that of clozapine, and
further studies into its antipsychotic value, if any, should be explored.
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INTRODUCTION
Schizophrenia
Schizophrenia is a mental disorder that consists of dysfunction in thought processes and
emotional regulation, and occurs in roughly 1% of the population (Simeone, Ward, Rotella,
Collins, and Windisch, 2015). Schizophrenia is characterized by its symptomology. An
individual may experience delusions, hallucinations, disorganized speech, and abnormal motor
activity. These particular symptoms are referred to as positive symptoms, indicating that they are
present. There are also negative symptoms, which indicate a lack of presence, such as social and
emotional withdrawal, lack of motor response, and avolition (American Psychiatric Association,
2013).
History of Psychosis and Schizophrenia
Psychosis has been described in various texts from early in human history. The first
known description of psychosis was found in religious scriptures of India around 1400 B.C.E.,
characterized by confusion and lack of self-control, but differed from confusion due to use of
physiologically and psychoactive substances, or manic-depressive illness (Gottesman, 1991).
Under the unitary theory of psychosis, all psychosis was considered symptomology of the same
underlying spectrum of mental illness until 1889, when Emil Kraepelin was the first to formally
characterize schizophrenia, which he referred to as dementia praecox, meaning precocial
dementia. Kraepelin described dementia praecox as a combination of other conditions: catatonia;
hebrephrenia; and dementia paranoia. This was also the first time that the disease was
characterized to have a specific neuroanatomical pathology (Adityanjee, Aderibigbe,
Theodoridis, & Vieweg 1999; Lavretsky, 2008). Kraepelin was among the first to differentiate
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manic depressive illness and dementia praecox, which, while both shared similar symptomology,
manic depressive illness main symptoms revolved around disordered mood, while dementia
praecox symptoms were functional and social disability (Lavretsky, 2008). It was in 1911 when
Eugene Bleuler first used the term schizophrenia, meaning “split mind”. While Kraepelin
believed that schizophrenia had a neurological pathology, Bleuler believed that it had a
psychological pathology, and characterized schizophrenia by fundamental symptoms, common
to all schizophrenia subtypes: cognitive disturbances; affective blunting; and ambivalence, and
associative symptoms: hallucinations; delusions; and catatonia (Adiyanjee, et al., 1999;
Lavretsky, 2008).
Kurt Schneider was one of the first researchers to look at schizophrenia longitudinally,
and took issue with the definition of schizophrenia created by Kraepelin and Bleuler. Their
definition could provide a diagnosis that was sometimes based on the psychological symptoms,
and sometimes based on the progression of the disease, while Schneider’s research showed that
the course of the disease had a general sequence of clinical states, and should be diagnosed by
the symptoms, as well as the progression (Hoenig, 1983). Schneider’s list of symptoms would
help improve interrater reliability of diagnosing schizophrenia, and his contributions are still
used in diagnostic criteria today (Adiyanjee, et al., 1999).
Neurotransmitters Involved in Schizophrenia
The exact causes of schizophrenia remain unknown, although there are several
neurotransmitters that are associated with the disease state (Lavretsky, 2008). Dopamine has
been implicated to be associated with schizophrenia soon after discovery of antipsychotic drugs
(APDs). Positron emission tomography (PET) and single photon computerized tomography
(SPECT) scans of the brains of drug naïve individuals with schizophrenia have shown that there
2

is an increase in dopamine D2 receptors in the striatum, as well as a decrease in the receptor
affinity for D2, with these differences becoming more pronounced with age (Laruelle, 1998).
Other studies have found that changes in density of dopamine D1 receptors in the prefrontal
cortex that may be associated with the negative symptoms and cognitive deficits associated with
schizophrenia (Howes & Kaspur, 2009).
Serotonin is another neurotransmitter implicated in the pathology of schizophrenia, which
has been implicated since the discovery that the hallucinogenic drug, LSD, is a serotonin agonist
(Lavretsky, 2009; Harrison, 1999). Some research has found evidence of excessive serotonin
receptors in the anterior cingulate cortex, and the dorsolateral frontal lobe in the brains of
individuals with schizophrenia (Gurevich & Joyce, 1997; Eggers, 2013). Additionally, many of
the drugs used for the treatment of schizophrenia have a high affinity for serotonin receptors as
antagonists and have demonstrated reduction in positive symptoms, and to a lesser effect,
negative symptoms (Lavretsky, 2009). However, many of these drugs have action on multiple
receptor sites, and antipsychotic efficacy may be a result of multiple mechanisms of action.
Glutamate is one of the primary excitatory neurotransmitters of vertebrate brains, which
accounts for a majority of the synaptic connections in the brain (Meldrum, 2000). Drugs that
cause dysfunction of glutamate transmission, such as PCP, ketamine, and MK-801, have been
found to cause psychosis in humans, and cognitive impairments that resemble negative
symptoms in preclinical models (van der Staay, Rutten, Erb, & Blokland, 2011). Glutamate binds
to several receptor sites in the brain, such as the NMDA receptors. These receptors have been
found to be dysfunctional in pre and post synaptic sites in individuals with schizophrenia
(Moghaddam and Javitt, 2012). While in the dopamine model of schizophrenia, deficits are
usually limited to the dorsolateral prefrontal cortex, and the striatum; the glutamate model of
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schizophrenia shows deficits throughout cortical and subcortical brain regions (Javitt, 2009;
Moghaddam and Javitt, 2012).
There are multiple neurotransmitters in dysfunction in the schizophrenic brain.
Consequently, the most effective treatments for schizophrenia have been drugs that have
multiple mechanisms of action. APDs are the primary treatment for schizophrenia. APDs fall
into two different sub-classes: typical APDs, also known as first generation APDs; and atypical
APDs, also known as second generation APDs.
The First Drug Treatments for Schizophrenia
Chlorpromazine is the first APD that was marketed for the treatment of schizophrenia.
After the drug was developed in 1950, it was first used in combination with morphine to reduce
the usage of an anesthetizer during surgery, where it was discovered that patients that had been
treated with chlorpromazine experienced less preoperative and postoperative anxiety (Swazey,
1972). Chlorpromazine was found to have anxiolytic, antispasmodic, sedative, and antiemetic
properties, which made it a useful as a surgical drug. Researchers would later discover its use in
reducing agitation in individuals suffering from manic episodes (Swazey, 1972; Lopez-Monoz,
et al. 2005).
Prior to the use of APDs, attempted pharmacological treatments for many mental
illnesses such as schizophrenia included compounds that were often supported by mainly
anecdotal accounts, and seldom addressed the core symptoms of the disorder. Treatments
included use of barbiturates on belligerent patients during manic or otherwise agitated episodes
to induce sleep; and hypoglycemic shock therapy, in which patients were given injections of
insulin to induce diabetic coma, which could be reversed by glucose syrup. In addition to
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hypoglycemic shock therapy, electroshock therapy was also used (Anderson, 2016). When the
antipsychotic actions of chlorpromazine was first discovered, it brought on the development of
several similar drugs, which were later characterized by their high binding affinity as antagonists
to the dopamine D2 receptors (Lehmann and Ban, 1997; Seeman, 2010). The use of
chlorpromazine and other first generation ADPs were also found to cause movement disorders,
known as extrapyramidal symptoms (EPS). These side effects include muscle spasms (dystonia);
tremors, or jerky movements (tardive dyskinesia); restlessness (akathisisa); and general slowness
of movement (bradykinesia) (Lieberman et al. 2005). Most of these movement disorders would
appear rather quickly as a patient takes the drug, however tardive dyskinesia, a condition
characterized by involuntary movements of the face and body, was only seen after being treated
for several years, and continues even after the drug is terminated (Anderson, 2016).
When clozapine was first developed in 1959, it was found to have very similar
neuroleptic effects to that of chlorpromazine, yet did not show the same involuntary movements
that were thought at the time to be an unavoidable component of APD treatment, which is why it
later became referred to as an atypical antipsychotic (Crilly, 2007). While atypical APDs can
cause these extrapyramidal symptoms, they do so with far less frequency than typical
antipsychotics. With select drugs, this may be due to their high binding affinity for the dopamine
D2 receptors (Kapur and Remington, 2001). However, there are several atypical antipsychotics
that do have high binding affinity for dopamine that do not exhibit these symptoms with the
same frequency as the first generation antipsychotics. Research has suggested instead, that the
reason ADPs show less extrapyramidal symptoms is due to their complex receptor binding
profiles (Meltzer, 2004). Although, atypical APDs are less likely to cause movement disorders,
they often carry risk of weight gain, new-onset type II diabetes, and metabolic dysfunction
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(Baptista, Kin, Beaulieu, and de Baptista, 2002). Clozapine, like many other atypical
antipsychotics, has a higher binding affinity to several serotonin receptors, in addition to affinity
for dopaminergic, histaminic, adrenergic, and cholinergic receptors. (Goudie, Cooper, Cole, and
Sumnall, 2007).
Chlorpromazine, in addition to many other typical APDs, is derived from the organic
compound phenothiazine, which has a history in the development of a number of different drugs
(Lopez-Monoz, et. al 2005). The first phenothiazine compound synthesized was methylene blue,
which had originally been used as a textile dye, before the discovery of its antimalarial properties
(Shen, 1999). In addition to methylene blue, there are many other compounds derived from
phenothiazine that have medical uses, aside from antipsychotics, yet are no longer used due to
their low therapeutic window. These compounds have been used as antihistamines (promazine;
promethazine), trypanocidals (trypan red), antihelmintics (phenothiazine), and antiparkinsonians
(diethazine) (Swayze, 1972). With such slight variations in the chemical structure of these
phenothiazine based compounds, they have shown a wide variety of uses in medicine over the
years.
The discovery of antipsychotics has improved the lives of those afflicted with mental
illness, yet it still comes at a great financial cost. People with schizophrenia deal with direct costs
of: hospitalization; follow up treatment; care givers; and drugs, as well as indirect costs related to
loss of productivity due to managing their symptoms. In the United States, the direct and indirect
costs of the disease have been growing steadily over the past years (Tajima-Pozo, de Castro
Oller, Lewczuk, and Montanes-Rada, 2015), with direct and indirect costs totaling over $62.7
billion as of 2002, with about 8% of that total being the cost of drugs (McEvoy, 2007). In the
areas developing world, making older, typical APDs available in the place of atypicals can
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significantly lower the cost of treatment, as well as repurposing old drugs that may have
antipsychotic efficacy (Chisholm, et al. 2008).
Before the Discovery of Chlorpromazine
While there are many drugs that are currently available for the treatment of
schizophrenia, the cost may be especially high for those in the developing world (Chisholm, et
al., 2008). Some preclinical trials have shown that there are other, more cost effective drugs that
may work in place of current APDs (Goudie, et al., 2007), and that there are many similar
compounds that have therapeutic value for a variety of ailments (Swayze, 1972). While the
results may be modest, there are many other antihistamines and phenothiazine compounds that
could be evaluated for their therapeutic effects in the treatment of schizophrenia and other
psychotic disorders.
Methylene blue is a phenothiazine compound that was originally used as a dye in textiles,
and became the first fully synthetic drug used in medicine (Howland, 2016). Methylene blue was
found effective in treating the symptoms of malaria, in addition to having several other medicinal
uses (Healy, 2002), such as reducing the symptoms of manic depressive psychosis (Narsapur,
and Naylor, 1983). More recently, it has been found to have some anxiolytic and antidepressant
effects (Eroglu, and Caglayan, 1997). Due to the calming and anxiolytic effects that methylene
blue may share with other phenothiazine compounds, such as chlorpromazine, there may be
some value in evaluating it against current APDs.
Several other phenothiazine derived drugs are still currently used in medicine, mostly in
the treatment of malaria, but also used as antiprotozoals, and antihelmintics, such as quinacrine.
While quinacrine is quite similar in structure to methylene blue and chlorpromazine, it does not
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share many of their sedative or agitation reducing features. Antimalarials that share features with
quinine, in that they cause many psychiatric features similar to psychosis and cognitive deficits
(Nevin & Croft, 2016). Quinacrine has also been shown to decrease sensitivity to prepulse
inhibition (PPI) testing in rats, similar to that of patients with schizophrenia, who have issues
with sensorimotor gating (Lee, Farooqui, Dawe, Burgunder, & Ong, 2009). Quinacrine would
likely be able to serve as a negative control for a comparison to the subjective effects of APDs
against other drugs in the antimalarial class.
Drug Discrimination
Drug discrimination is an operant conditioning procedure in which an organism is trained
to discriminate between the subjective effects of a drug from the solution in which it is delivered,
known as the vehicle. When using non-human animals for this procedure in an operant chamber,
the animal is taught to respond a certain way after given a drug in order to receive a
reinforcement, usually food. When the animal feels the subjective effects of the drug, it knows to
respond by pressing the drug appropriate lever to receive food, and when the animal is given the
vehicle that serves as the placebo, it will respond by pressing the non-drug lever for
reinforcement. Once an animal is trained to respond to the subjective effects of one drug, the
animal is then given novel drugs to examine if they will respond in a similar way while under the
subjective effects of the novel drug. If they respond in a similar manner, it may be likely that the
two drugs have similar pharmacological activity (Young, James, and Rosencrans, 2009). In this
way, drug discrimination assays can be used as a tool to determine the mechanisms of action of
novel drugs.
The panoply of receptor actions by clozapine, as noted earlier, appear to engender a
compound discriminative cue as studied in a drug discrimination procedure (Kelley & Porter,
8

1997; Prus, et al., 2016). When looking at other drugs that have a similar compound cue, it was
found that the antihistamine cyproheptadine had a similar binding profile to clozapine. When
these drugs were evaluated for their subjective effects in a drug discrimination trial, a dose of
cyproheptadine at 40 mg/kg fully substituted for a dose of clozapine in rats at 5 mg/kg (Kelley &
Porter, 1997; Goudie, et al. 2007). Although, this was a preclinical study, showing similarity of
these drugs in rats, it shows that drugs with similar receptor binding profiles can have similar
effects.
Several studies have established chlorpromazine as a discriminative cue in rats (Stewart,
1962; Overton, 1982; Porter et al., 1998; Porter et al., 2004). Porter et al. (1999) successfully
trained six rats to discriminate a 1.0 mg/kg IP dose of chlorpromazine from its vehicle in a two
lever discrimination task. When the rats were tested against various APDs, the atypical APDs
clozapine and olanzapine, fully substituted for chlorpromazine, as well as the typical APD
thioridazine, while the atypical antipsychotic raclopride, and typical antipsychotic haloperidol
only partially substituted for chlorpromazine, showing the chlorpromazine does share
discriminative stimulus properties with some atypical and typical APDs (Porter et al., 1999).
Clozapine has also been shown to be able to be able to form a discriminative cue
(Goudie, & Taylor, 1998; Porter, Varvel, Vaan, Philibin, & Wise, 2000; Porter, et al., 2005; Prus,
et al., 2005; Porter, & Prus, 2009). Prus et al. (2005) had trained nine rats to discriminate 5.0
mg/kg of clozapine from vehicle in a two lever discrimination task. The atypical antipsychotics
olanzapine, quetiapine, and ziprasidone, as well as the typical APDs thioridazine fully
substituted for clozapine, while there was partial substitution for the atypical APDs risperidone,
and sertindole, while typical antipsychotics chlorpromazine, fluphenazine, and haloperidol did
not substitute for clozapine. While many typical antipsychotics have been found to generalize to
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chlorpromazine (Porter, et al., 1999), and many atypicals have been found to generalize to
clozapine (Prus, et al. 2005), there has been less research looking at completely novel drugs with
calming properties to see how they generalize to current APDs that are available.
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RATIONALE
It has been close to 70 years since the discovery of chlorpromazine, and the therapeutic
effects of modern ADPs have not made substantial gains in therapeutic efficacy. Therefore, an
investigation into early compounds with putative APD-like effects is warranted. In particular,
few studies have re-evaluated such compounds in direct comparison to established APDs in
assays with strong predictive validity for determining mechanism of action, such as the drug
discrimination procedure. Current APDs can be evaluated for their subjective effects through the
use of drug discrimination procedures. The purpose of the present study is to evaluate the
subjective effects of the antimalarial drugs methylene blue and quinacrine, which are known to
have similarity in chemical structure, in rats trained to discriminate the APDs chlorpromazine,
and clozapine to see if the test drugs show similarity in their subjective effects to that of the
current APDs by way of stimulus generalization. If these drugs do generalize to current
antipsychotic medication, it may indicate that there is therapeutic value in further evaluating
these drugs as antipsychotic alternatives.

11

MATERIALS AND METHODS
Animals
Twenty male Sprague-Dawley rats were used for this study. Ten of which were trained to
discriminate chlorpromazine at 1.0 mg/kg from vehicle (Group 1), and the other ten of which
were trained to discriminate clozapine at 1.25 mg/kg from vehicle (Group 2). The rats were
individually housed in a temperature and humidity controlled room, on a 12 hour light to dark
cycle, with the lights on from 5:00 AM to 5:00 PM. Rats were put on restricted feeding to
achieve 85% free feeding weight. Water was available ad-lib in their home cages. Rats were fed
following daily sessions that occurred around the same time every day.
Apparatus
Eight standard rat operant chambers were used (ENV-008-VP, MED Associates, St.
Albans, VT) contained in sound attenuating cabinets for this study (ENV-018MD, MED
Associates, St. Albans, VT). Cabinets were equipped with fans for masking noise and
ventilation, and all equipment was controlled by MED-PC IV software. The operant chambers
(30 cm long × 24 cm wide × 29 cm high) were constructed of a Plexiglas top and side door
panels, and other walls and components made of stainless steel. A concealed light bulb located
near the top of the operant chamber provided illumination during all training and test sessions.
Two retractable levers (drug and vehicle levers) were located on either side of a food hopper
centered on the stainless steel wall of the chamber. Food reinforcement consisted of 45 mg food
pellets (Dustless Precision Pellets, Rodent Grain-Based Diet, Bio-Serv, Flemington, NJ)
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Drugs
Generalization testing was conducted with chlorpromazine hydrochloride (0.0625; 0.125;
0.5; 1.0; 2.0; and 4.0 mg/kg), clozapine (0.15625; 0.3125; 0.625; 1.25; 2.5; and 5.0 mg/kg);
methylene blue – tetramethylthionine chloride (7.5; 15.0; 30.0; and 60.0 mg/kg); quinacrine
dihydrochloride (1.0; 10.0; and 30.0 mg/kg) All drug doses were based on previous literature (Al
Asmari, Al Sadoon, Obaid, Yesunayagam; & Tariq, 2017; Overton, 1982; Porter, et al., 1999; ;
Porter, Varvel, Vann, Philibin, & Wise, 2000; Oz, Lorke, Hasan, & Petroianu, 2011). All drugs
will be purchased from Sigma-Aldrich, St. Loius, MO, except clozapine which was purchased
from Ascent Scientific, Bristol, UK. The salt form of chlorpromazine, methylene blue, and
quinacrine was used, while the base form of clozapine was used. All drugs were dissolved in
water with a few drops of lactic acid and sodium hydroxide to raise the pH of the solution above
5.5. All drugs were administered intraperitoneally (IP) at a volume of 1.0 ml/kg of body weight,
with the exception of chlorpromazine also being administered subcutaneously (SC) after the first
30 training sessions (see below). All drugs were administered 30 minutes before test sessions
(Overton, 1982), unless otherwise noted.
Magazine Training
Rats were placed in the operant chamber in which food was delivered to them every 60
seconds (fixed time 60), with no levers available. This was intended to train the rats to associate
the sound of the food hopper with the availability food reward. This occurred over one session.
Lever Press Training
During lever press training, the center lever was available, while the left and right levers
were retracted, as they were used later when they were paired with the drug and vehicle. For
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every lever press the rat makes, it was given a food pellet as a reinforcement (Fixed Ratio-1).
The session concluded when the rat received 30 food pellets, or when 15 minutes elapsed. As the
rats learned the lever pressing behavior, the fixed ratio to receive the food reinforcement was
increased until the rats reliably lever pressed 30 times to receive a food pellet (Fixed ratio-30).
Single Lever Training
During single lever training, the rats were be given an intraperitoneal (IP) injection of
either their respective training drug, 1.0 mg/kg chlorpromazine for group 1, and 1.25 mg/kg
clozapine the group 2, or vehicle (consisting of deionized water with a few drops of lactic acid
and sodium hydroxide) in it thirty minutes prior to their training session. The rats had one of the
left or right levers assigned to the drug condition and the opposite lever assigned to the vehicle
condition. The lever assignment was counterbalanced among the rats. The rats were tested on a
single-double alternating design, on the drug (D), and vehicle (V) for training sessions (D-V-DD-V-V-D-V). After the animals successfully received 30 food pellets on an FR-30 for seven of
the eight sessions, they moved on to discrimination training.
Two Lever Training
During two lever discrimination training, the rats were injected with either their
respective training drug or vehicle, and presented with the right and left lever both available. The
two lever training continued to use a single-double alternation design. These trials used an FR30, in which if the rat pressed the incorrect lever, the count on the condition-appropriate lever
would reset, and the rat had to press 30 more times in order to receive a food reinforcement. The
rats had to complete the following criteria for five of six consecutive sessions: the first
completed fixed ratio requirement must be on the condition appropriate lever; the rat must have
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had a response rate of 0.08 responses per second and, and the rat must have completed 80% of
their responding on the condition appropriate lever during the given session. These conditions
continued throughout the course of the study to make sure that the rats retain discriminability
among the conditions.
During the course of the two lever training, the group 1 had to undergo several phase
changes, as during the first 30 sessions, nine out of the ten rats would fail to discriminate each
session, At session 32, the training dose was increased to 2.0 mg/kg via IP based on the dose
used by Goas and Boston (1978), however this appeared to make no difference in the ability for
the rats to discriminate. At session 52, the route of administration was changed from IP to SC,
but all but two rats were completely rate suppressed by this change. At session 54, the dose was
lowered to 1.0 mg/kg via SC. The rats were still performing below 5 responses per minute, and
so at session 62, the dose was lowered to 0.5 mg/kg, as this dose has still found to partially
substitute for the 1.0 mg/kg dose in previous literature (Porter, et al., 1999).
Substitution Testing
When the rats had successfully completed two training sessions, a test session was given.
The rat was given one of the test drugs via IP or SC injection, and the rat was put in the operant
chamber with a two lever choice after waiting for the appropriate pretreatment time for the drug.
The first FR30 completed on a lever (with a press to the opposite lever resetting the counter)
resulted in the end of the session. The length of the session depended on how long it took the rat
to complete an FR-30, or the test session would end when 15 minutes had passed, regardless of
whether or not they had completed an FR-30. Doses of drugs began with the drug vehicle and
were subsequently tested in an escalating order.

15

Data Analysis
The percent drug lever responding for drug and non-drug levers, the responses per minute
(RPM), and the lever on which the first FR-30 schedule were completed and recorded for each
training and test sessions. Percent drug appropriate responding and RPM was reported as means
and standard error of the mean (SEM) in dose-response curves. Full substitution was defined as
80% or greater drug appropriate responding; and partial substitution was defined as above 60%
drug appropriate responding and below 80% drug appropriate responding. As the drug
discrimination procedure was designed to evaluate the novel compounds for the subjective
effects of their respective training drugs, the drugs were assessed on whether they met criteria for
full, partial, or no substitution, as opposed to statistical significance, to determine the percent of
training drug appropriate responding (Glennon, and Young, 2011). Drugs that produced full
substitution had the ED50 value calculated for the dose response curve using a least-squares
linear regression analysis. One factor repeated measures analysis of variance (ANOVA) tests
were conducted to look at changes in the response rates, with Dunnett’s multiple comparison
tests conducted to identify significant differences in the changes among the response rates
between vehicle and each dosage of the drug tested. Rate comparisons were calculated using
Prism Graphpad 8.1.2 (San Diego, CA).
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RESULTS
Group 1: Chlorpromazine Drug Discrimination Training
Out of the ten rats trained to discriminate 1.0 mg/kg administered via IP injection
chlorpromazine from its vehicle, two were able to meet the training criteria. After a month of
additional training, all ten rats had the dose increased to 2.0 mg/kg via IP injection, in which one
more rat was able to meet training criteria. Chlorpromazine administration was then changed
from 30 minutes of pretreatment time to 60 minutes of pretreatment time, which had no effect on
performance. Many of the rats began to exhibit rate suppressing effects of the 2.0 mg/kg dose,
but did not do so with consistency, experiencing rate suppression on the drug one day, but not
the next. The route of administration was subsequently changed from an IP injection to an SC
injection. All rats began to succumb to rate suppressing effects at this time, so the dose was once
again lowered to 1.0 mg/kg, administered via SC. The rats continued to experience rate
suppression at the 1.0 mg/kg dose, so the dose was once again lowered to 0.5 mg/kg via SC
injection. After being acclimated to the 0.5 mg/kg SC dose, five more rats made discrimination
criteria. Including the five phase changes, eight of the ten rats made criteria in 55.1 sessions
(SEM = ± 12.2). Two rats failed to make discrimination criteria and were excluded from the
study (See Figure 1).
Group 1: Chlorpromazine Generalization Testing
Only one of the eight rats that made criteria had completed the chlorpromazine
generalization testing, therefore it was not possible to depict a generalization curve based on the
averages of the drug discrimination testing for this group.
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Group 2: Clozapine Drug Discrimination Training
Out of the 10 rats that were trained to discriminate 1.25 mg/kg clozapine from its vehicle,
nine rats were able to meet the training criteria within a mean of 19.1 sessions (SEM = ± 2.6).
One rat failed to meet discrimination criteria and was removed from the study (See Figure 2).
Group 2: Clozapine Generalization Testing
For the nine rats tested clozapine produced full generalization, 80% drug lever
responding or above, for clozapine at the training dose of 1.25 mg/kg (ED50 = 0.5094 mg/kg).
Partial generalization, between 60 and 80% drug lever responding, occurred to the 0.3125 mg/kg
(75.00% [SEM = ± 15.43]), and 2.5 mg/kg doses (76.07% [SEM = ± 14.42]). A significant
decrease in response rate compared to vehicle occurred at the 5.0 mg/kg dose (F [6, 48] = 4.84, p
< 0.001) (See Figure 3).
Group 2: Chlorpromazine Generalization Testing
In the four rats tested partial generalization for clozapine occurred with a 2.0 mg/kg
(78.75% [SEM = ± 22.05]), and 4.0 mg/kg (77.55% [SEM = ± 12.36]) doses of chlorpromazine.
The tests had also indicated that 3 out of 4 rats had full generalization at the 2.0 mg/kg dose,
while only two of them exhibited full generalization at the 4.0 mg/kg dose. There was a
significant difference in responding relative to vehicle chlorpromazine (F [6, 18] = 3.502, p =
0.0179), however a post-hoc analysis did not reveal differences between each dose and vehicle
(See Figure 4).

18

Group 2: Methylene Blue Generalization Testing
In the five rats tested partial generalization for clozapine occurred at the 7.5 mg/kg
(63.96%, [SEM = ±18.91]) dose of methylene blue. Among the tests, only one rat displayed full
generalization at the 7.5 mg/kg dose. There was no significant change in responding relative to
vehicle at any of the doses of methylene blue (F [3, 12] = 2.125, p = 0.1504). However, rate
suppression occurred for one rat, and in different rats at each of the three doses that were tested
(See Figure 5).
Group 2: Quinacrine Generalization Testing
In the three rats tested, quinacrine did not fully or partially substitute for the 1.25 mg/kg
clozapine training dose, with the highest drug lever responding at the 30 mg/kg dose (43.77%
[SEM = ± 19.57]). There was no significant change in responding at any of the doses tested (F
[3, 12] = 1.313, p = 0.3157) (See Figure 6).
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DISCUSSION
Group 1: Chlorpromazine Generalization
The rats from group one were successfully able to establish chlorpromazine as a
discriminative stimulus, which is supported by previous literature (Stewart, 1962; Porter, et al.,
1999; Porter, et al., 2005), but only after several phase changes. Eight of ten rats acquired the
discrimination at a mean 55.1 training sessions at the 0.5 mg/kg SC dose, which was much
longer that the 29.7 training sessions used by Porter et al. (1999) at the 1.0 mg/kg IP dose. There
first phase change could have failed due to increasing the time, as opposed to shortening the
time, as in Overton (1982), in which the pretreatment time for rats given 2.0 and 4.0 mg/kg
chlorpromazine to discriminate a T-maze was only 20 minutes. This is highly unlikely, as the
rats could be seen succumbing to the rate suppressing effects of the 2.0 mg/kg via SC of
chlorpromazine within the first ten minutes of their pretreatment time in the present study.
The route of administration might have accounted for this. Some drugs that are taken in
through the digestive system, whether it be orally, or intraperitoneally, may be subject to first
pass metabolism, and have their active metabolites degrade in the gut or liver before being able
to exerting their psychoactive effect. Certain drugs are more susceptible to first pass metabolism,
chlorpromazine has been found to be less stable in plasma concentrations in humans that have
taken the drug orally, compared to intramuscular (IM) injection (Dahl & Standjord, 1977), which
shows that the route of administration in administering chlorpromazine can affect biological
availability. Additionally, chronic administration can be an issue, as an organism may become
tolerant to drug effects over time. Rats given increasing doses of chlorpromazine over a 40 week
period have been able to take up to 200 mg/kg via IM (Boyd, 1960), while other studies have
shown that the lethal dose in 50% of rats (LD50) for chlorpromazine for other routes of
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administration is 142 mg/kg orally; 75 mg/kg SC; 58 mg/kg IP; and 23 mg/kg IV (Lewis & Sax,
2004). While Lewis and Sax (2004) did not include the LD50 for IM dosages, 200 mg/kg IM is
still much higher than even the highest LD50 of chlorpromazine at 142 mg/kg orally. The rats of
this study tolerating a dose of chlorpromazine at the 2.0 mg/kg level is not very likely, as if they
had developed a tolerance, they would not likely be able to discriminate at the lower 0.5 mg/kg
dose.
There is evidence in the literature for chlorpromazine, among other typical APDs not
being easily established as a discriminative stimulus. Harris and Balster (1971) were unable to
get rats to discriminate chlorpromazine at the 1.0 mg/kg via IP dosage in a two lever operant
chamber. McElroy, Stimmel, and O’Donnell (1978) were able to establish the typical APD
haloperidol at a discriminative stimulus in rats in a mean of 45 training sessions, while Donahue,
Webster, Hillhouse, Oliveira, and Porter (2019) were able to establish haloperidol as a
discriminative stimulus in mice in a mean of about 31 training sessions at the 0.05 mg/kg SC
dose. However, the mice of this study eventually failed to retrain discriminability. As haloperidol
has been show to generalize in chlorpromazine trained rats (Porter, et al., 1999), as well
chlorpromazine being generalized in haloperidol trained rats (McElroy, et al., 1978), indicates
that these two drugs likely have a similarity in pharmacological action, while Donahue, et al.
(2019), shows that haloperidol does not display a particularly strong discriminative stimulus, in
which discriminability may be difficult to maintain. The results may be species, drug, or even
route of administration specific, however, the previous literature does show there have been
difficulties establishing typical antipsychotics as discriminative stimuli, and this may be due to a
failure to retain discriminability, which should be further explored.
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Another likely factor contributing to the difficulty in establish typical antipsychotics as
discriminative stimulus is the antagonism of dopamine receptors. Porter et al. (1999), was not
able to get rats to discriminate 2.0 mg/kg, due to the rats responding below five per minute
during initial two lever training, which is why the dose was reduced to 1.0 mg/kg. Additionally,
the study had showed that at the 1.0 and 2.0 mg/kg doses, there was a significant decrease in
response rate compared to vehicle. Donahue et al. (2019) showed similar results in the
discrimination of haloperidol in mice. The training dose of 0.05 mg/kg did not any significant
changes in response rate, the 0.1 and 0.2 mg/kg doses showed significant rate suppression
compared to that of vehicle. Previous studies were able to establish dosages of chlorpromazine as
discriminative stimulus as high as 4.0 mg/kg (Overton, 1982; Stewart, 1962), although the
discrimination procedures in these studies used a shock avoidance discrimination procedure.
These studies may show that shock avoidance is a more salient reinforcement than a food
reward, but do not necessarily show that using a higher dose is more salient in discrimination.
Group 2: Clozapine Generalization
The rats from group two were successfully able to establish clozapine as a discriminative
stimulus, which is supported by previous literature at the 5.0 mg/kg dose (Kelley and Porter,
1997; Goudie and Taylor, 1998; Prus, et al., 2004; Goudie, et al. 2007), and the 1.25 mg/kg dose
(Porter, et al., 2000; Prus, et al., 2004; Prus, et al. 2006), which is more selective for atypical
antipsychotics. Nine out of ten rats were able to acquire the two lever discrimination for the 1.25
mg/kg dose in a mean of 19.1 training sessions, which is faster than Prus, et al. (2004), which
had achieved discrimination in about 55 sessions, as well as slightly faster than Porter, et al.,
which achieved discrimination in about 28 sessions. The discriminative stimulus was dose
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dependent with an ED50 of 0.5094 mg/kg, and full generalization for only the training dose of
1.25 mg/kg.
Group 2: Chlorpromazine
Chlorpromazine was found to partially substitute for clozapine at the 2.0 and 4.0 mg/kg
dosages in the four of the rats that were tested. This does not follow along with previous research
for clozapine with a training dose of 1.25 mg/kg, as Porter, et al. (2000) found that
chlorpromazine did not produce substitution in clozapine-trained rats, although that study did not
include a 2.0 mg/kg dose, and there was rate suppressing effects for all seven rats in that study at
the 4.0 mg/kg dose of chlorpromazine. In the current study, there is a significant difference in
responding when the clozapine trained rats were given chlorpromazine, but post-hoc analysis did
not find that it occurred at any specific doses.
Drug discrimination studies that have used 5.0 mg/kg of clozapine as the training drug,
which has shown to be less sensitive to the differences between typical and atypical
antipsychotics (Goudie and Taylor, 1998; Prus, et al., 2005), also found that chlorpromazine does
not substitute for clozapine. Other studies have shown that clozapine will produce substitution in
rats trained on chlorpromazine (Porter, et al. 1999), yet the substitution for clozapine trained rats
testing chlorpromazine has not been symmetrical (Porter, et al., 2000; Prus, et al, 2005).
These previous studies had both looked at two lever discrimination for clozapine trained
rats, however, there is some evidence for rats substituting clozapine. In a three lever
discrimination task, Porter et al. (2005) was able to get rats to discriminate 1.0 mg/kg
chlorpromazine versus 5.0 mg/kg clozapine versus vehicle. This study found that chlorpromazine
at the 4.0 mg/kg dose did partially generalized to clozapine.
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Group 2: Methylene blue
In the five rats that were tested, methylene blue was found to partially substitute at 7.5
mg/kg for clozapine for four of the rats. While five of the rats had tested for methylene blue,
three of experienced rate disrupting effects, and each of them had experienced it at a different
dose. This study may be the first time methylene blue has been used a testing compound in a
discriminative stimulus assay, but it’s not the first time that methylene blue has been compared
to other APDs: Klamer, Engel, and Svensson (2004) had found that methylene blue at 50 mg/kg
and 100 mg/kg dosages via IP reversed PPI of the acoustic startle response caused by
phencyclidine in mice.
Methylene blue has also been explored for anxiolytic and antidepressant properties. In
rats that were subjected to an elevated plus maze, a preclinical assay designed to measure anxiety
by watching how much time an animal spends in the open sections of the maze or the closed
section of the maze, it was found the methylene blue had dose dependent effects. At low doses,
7.5 mg/kg, 15 mg/kg, and 30 mg/kg via intravenous (IV) injection, the rats had spent a
significantly more time in the open arms compared to baseline, which indicates these doses
likely have anxiolytic properties, yet at 60 mg/kg via IV, the rats spent significantly more time in
the enclosed arms compared to baseline, which may indicate anxiogenic effects. Additionally, 60
mg/kg was found to cause a significant decrease in locomotor activity (Eroglu & Caglayan,
1997). During the course of the current study, two of the rats were given a 60 mg/kg test
sessions, but failed to respond when put in their operant chamber, so that dose was not given to
the remaining rats. Due to the low dose of 7.5 mg/kg partially substituting for clozapine, it may
be worth exploring even lower doses to see it increases drug lever responding, in addition to
seeing if there are still selective rate disrupting effects for lower doses for some of the rats.
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While there are many other APDs that generalize for clozapine in rats, there is also
evidence for full substitution by the antihistamines cyproheptadine and promethazine, and the
antidepressants, amitriptyline and mianserin for clozapine at the 5.0 mg/kg dose (Kelley &
Porter, 1997). The tricyclic antidepressant imipramine has been found in some studies to
partially substitute for clozapine in rats (Kelley & Porter, 1997), and not at all in other studies
(Nielson, 1988). Methylene blue does have some antidepressant and anxiolytic properties
(Eroglu & Çaglayan, 1997; Oz, et al., 2011), and despite being used in medicine for 100 years,
little is known about the receptor binding profile of methylene blue, aside from it likely binding
to GABAA receptors (Chen, Liu, Yang, Dillon, & Huang, 2017). The discriminative stimulus of
clozapine relies on its complex binding profile which acts on a range of receptors. Previous drug
discrimination studies have indicated that clozapine’s discriminative stimulus properties can be
mediated by muscarinic, alpha1 andrenergic, or dopaminergic D2 antagonism (Porter, Prus, Vann,
& Varvel, 2005), and more recently studies have implicated serotonergic 5-HT2A inverse
agonism, and dopaminergic D4 antagonism (Prus, et al., 2016). This complex receptor binding
affinity is likely what it has in common with the various antidepressants and antihistamines that
have substituted for it by the animals of the previous drug discriminations, and possibly what it
shares in common with methylene blue as well.
Group 2: Quinacrine
In the four rats tested, quinacrine was not found to substitute for clozapine. Quinacrine
falls under two chemical families, the phenothiazines, of which it shares three heterocyclic rings,
and its antihelmintic properties (Swazey, 1974), and the quinolines, which looks chemically
similar to phenothiazine but has two heterocyclic rings instead of three, which it shares
antimalarial properties with, and includes other drugs such as quinine, chloroquine, and
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mefloquine. The quinoline antimalarials have been found to be linked to depression, confused
states, insomnia, anxiety, and delusions (Nevin & Croft, 2016). Quinacrine decreasing sensitivity
to PPI in rats does help to provide further evidence to suggest that, aside from methylene blue,
antimalarial drugs do not appear to have antipsychotic efficacy (Lee, et al., 2009).
Malaria is a disease that is characterized by fever, loss of energy, emesis, and in more
extreme cases, seizures and coma. Malariotherapy had also been used as a treatment for
schizophrenia, among other conditions, by use of fever, seizures, and coma, as treatments for
psychosis, in the pre-chlorpromazine era (Freitas, et al., 2014). Malriotherapy had been so
effective at treating individuals with neurosyphilis and schizophrenia, Julius Wagner-Jauregg
had won the 1927 Nobel Prize in medicine for developing the treatment (Tsay, 2013). To say that
malaria induced sedative like effects, while quinacrine and other quinoline antimalarials reduce
the effects of Malaria by inducing agitation, would be a gross oversimplification of the treatment
of the disease, but one that follows along the logic of early scientific merit.
Limitations
This study was limited by several factors. Despite chlorpromazine being described as
having a robust discriminative stimulus, the drug was not able to be established as a
discriminative stimulus without great difficulty, or reliability. It cannot be ruled out that the
effects of several phase changes likely affected how the rats will generalize novel drugs. The
clozapine trained rats despite having more readily acquired the discrimination, had their share of
difficulties as well, such as the chlorpromazine partially substituting at the higher doses for
clozapine, despite not having a precedent for that in previous literature in a two lever
discrimination procedure. This illustrates how the drug discrimination paradigm is affected by
individual components of a compound cue, and while it may be useful for exploring similarities
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in the subjective effects of drugs due to similarity in pharmacological profile, but does not
elucidate the specific mechanism of action of these drugs. Drug discrimination can be useful in
determining behavioral effects of drugs, however there is not yet it has not been determined the
link between the discriminative stimulus effects of antipsychotic drugs, and their therapeutic
efficacy.
Methylene blue having a partial generalization to clozapine is of interest in this particular
study, it should also be noted that to confirm that these drugs do indeed have similar receptor
activity, positive and negative controls should be used to confirm the findings. Using another
atypical antipsychotic, such as olanzapine that has previously been shown to generalize to
clozapine (Prus, et al., 2005), would confirm that drug lever responses are due to similarity of
receptor activity. A negative control could be established by a drug with known pharmacological
dissimilarity to clozapine, such as amphetamine, which has been shown to have its
discriminative stimulus effects antagonized by clozapine, among other antipsychotics (Nielsen &
Jepsen, 1985) would help to confirm that lever pressing on drug lever was not due to
dissimilarity from the control condition.
Finally, if a drug such as methylene blue is indeed found to have therapeutic effects in the
treatment of schizophrenia, or other illnesses, it may not be of much value to patients that
experience the drugs unpleasant subjective effects. Individuals with schizophrenia report higher
levels of dissatisfaction and perceived adverse effects with typical antipsychotics compared to
that of atypical antipsychotics (Hellewell, 2002). This should serve as a reminder to the point
that new drug treatment should not be worse than the illness.
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Future research
This study has several findings that could be useful in the development of future research.
Methylene blue partially substituting for clozapine is noteworthy, as there are a number of
different experiments that can be performed to further explore antipsychotic, antidepressant, or
anxiolytic value of methylene blue. Additionally, it may be of interest to examine the
psychoactive effects of the different antimalarial drugs, as their mechanism of action is not well
understood, and if quinacrine or other quinoline antimalarials do exert adverse psychiatric effects
that may be worth exploring as a putative deficit inducer.
Conclusions
The present study sought to further explore the discriminative stimulus properties of
current APDs. Despite being well characterized in the literature, antipsychotic medicine is far
from perfect, as current antipsychotic medicine only treats symptoms of schizophrenia, and
asymmetrically treats positive symptoms more so than negative symptoms. Many individuals
that suffer from schizophrenia also struggle with the side effects of the medications that they
have to take. Finding the right medication for each individual can also be quite difficult, as not
all antipsychotics work effectively in all individuals. It is important for us to find the treatment
for the right person. The use of methylene blue, may not be right treatment for all people who
experience psychosis, but it may have therapeutic value for some. The findings of this study
suggest methylene blue may exhibit antipsychotic-like effects, further research is needed in
models that are specifically predictive of antipsychotic activity.
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Until a treatment is discovered that is more effective than the drugs that we have
available today, there should be a continued effort to find new drugs, and drug discrimination
can be an effective tool for exploring the pharmacological action of new drugs.
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Figure 1: Mean % chlorpromazine lever responding for two lever training in rats trained to
discriminate chlorpromazine from vehicle. The x-axis indicating the number of sessions for the
drug and vehicle testing, and the y-axis indicates the percent of drug lever responding. The
number in parenthesis indicates the number of rats that had yet to meet criteria, otherwise the
number of rats is equal to N. The dotted lines across the x-axis indicating phase changes: the first
one indicating change in training dose from 1.0 mg/kg via IP to 2.0 mg/kg via IP; second
indicating change in route of administration from IP to SC; third indicating change from 2.0
mg/kg via SC to 1.0 mg/kg via SC; and fourth indicating 1.0 mg/kg SC to 0.5 mg/kg SC.
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Figure 2: Mean % clozapine lever responding for two lever training in rats trained to
discriminate 1.25 mg/kg clozapine from vehicle. The x-axis indicating the number of sessions for
the drug and vehicle testing, and the y-axis indicates the percent of drug lever responding. The
number in parenthesis indicates the number of rats that had yet to meet criteria, otherwise the
number of rats is equal to N.
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Figure 3: Generalization results for clozapine in rats trained to discriminate 1.25 mg/kg
clozapine from vehicle in a two lever drug discrimination task. Mean percent drug lever
responding is shown in the upper panel, and mean responses per second are shown in the lower
panel. The dashed line at 80% indicates full generalization to the drug lever. Prior to
generalization testing, control tests were conducted with the clozapine training dose and vehicle.
Rats with response rates below 5 responses per minute in a given test session were not included
in the % drug lever data.
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Figure 4: Generalization results for chlorpromazine in rats trained to discriminate 1.25 mg/kg
clozapine from vehicle in a two lever drug discrimination task. Mean percent drug lever
responding is shown in the upper panel, and mean responses per second are shown in the lower
panel. The dashed line at 80% indicates full generalization to the drug lever. Prior to
generalization testing, control tests were conducted with the chlorpromazine training dose and
vehicle. Rats with response rates below 5 responses per minute in a given test session were not
included in the % drug lever data.
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Figure 5: Generalization results for methylene blue in rats trained to discriminate 1.25 mg/kg
clozapine from vehicle in a two lever drug discrimination task. Mean percent drug lever
responding is shown in the upper panel, and mean responses per second are shown in the lower
panel. The dashed line at 80% indicates full generalization to the drug lever. Prior to
generalization testing, control tests were conducted with the methylene blue training dose and
vehicle. Rats with response rates below 5 responses per minute in a given test session were not
included in the % drug lever data.
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Figure 6: Generalization results for quinacrine in rats trained to discriminate 1.25 mg/kg
clozapine from vehicle in a two lever drug discrimination task. Mean percent drug lever
responding is shown in the upper panel, and mean responses per second are shown in the lower
panel. The dashed line at 80% indicates full generalization to the drug lever. Prior to
generalization testing, control tests were conducted with the quinacrine training dose and vehicle.
Rats with response rates below 5 responses per minute in a given test session were not included
in the % drug lever data.
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IACUC #: 350 PROPOSAL TITLE: Behavioral effects of classical and novel antipsychotics
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